In this present study we show that targeting ANXA1 with the humanised monoclonal antibody, MDX-124, can reduce cell growth in ANXA1-expressing cancer cells both in vitro and in vivo, providing further evidence that ANXA1 is a valid target for therapy in cancer. The gene discussed is ANXA1; the disease is cancer.